Results 151 to 160 of about 13,103,023 (178)
Some of the next articles are maybe not open access.

Hepatitis B Virus Drug Resistance to Current Nucleos(t)Ide Analogs: Mechanisms and Mutation Sites

Hepatology Research, 2011
Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed.
Lihui, Deng, Hong, Tang
exaly   +3 more sources

Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation

Hepatology Research, 2022
AbstractAimWe retrospectively investigated patients with administration of nucleos(t)ide analogs (NAs) for prevention of or against hepatitis B virus (HBV) reactivation, and their clinical outcomes after cessation of the NA.MethodsWe enrolled 180 patients who were positive for HBsAg when they started immunosuppressive therapy or chemotherapy and an NA ...
Takanori Suzuki   +20 more
openaire   +2 more sources

[Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020
Hepatitis B virus (HBV) infection is the most important risk factor for cirrhosis and hepatocellular carcinoma (HCC) in Chinese patients. Interferon (IFN) and nucleos(t)ide analogues (NAs) are two major regimens for chronic hepatitis B (CHB). A large number of clinical studies have previously confirmed that the risk of HCC in CHB patients can be ...
Z H, Liu, J, Sun
openaire   +1 more source

Performance of Serum HBcrAg in Chronic Hepatitis B Patients With 8-Year Nucleos(t)Ide Analogs Therapy

Clinics and Research in Hepatology and Gastroenterology, 2019
This study aimed to investigate long-term kinetics of serum hepatitis B core-related antigen (HBcrAg) and its correlation with serum hepatitis B surface antigen (HBsAg) in a real-world cohort of patients who had received over 8 years of nucleos(t)ide analogs(NAs) therapy.This was a retrospective study.
Juan Liao, En-Qiang Chen, Hong Tang
exaly   +3 more sources

Consequences of Persistent HBV infection in HIV: the Double-Edged Sword of Nucleos(t)ide Analogs

Future Virology, 2012
A variety of nucleos(t)ide analogs (NA) are available to treat HBV infection, the majority of which are also active against HIV, and when alone or in combination, have proven to actively suppress circulating HBV. However during treatment, especially among HIV-infected patients, the persistent nature of replicating intracellular DNA and lack of HBsAg ...
Anders Boyd   +2 more
openaire   +1 more source

Long‐term nucleos(t)ide analog(s) monoprophylaxis in Delta coinfected liver transplant recipients

Transplant Infectious Disease, 2017
I have read with great interest the article by Cholongitas et al.1 discussing an anti-hepatitis B surface antigen (HBsAg) immunoglobulins (HBIG)-sparing approach in hepatitis Delta virus (HDV) coinfected liver transplantation (LT) recipients. In the HBIG prophylaxis era, HDV coinfection was originally recognized as a protective factor against the ...
openaire   +2 more sources

Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy

Antiviral Research, 2011
The evolutionary and mutational pattern of full hepatitis B virus (HBV) quasispecies during sequential nucleos(t)ide analog (NUC) therapy remains unclear. In this study, full-length HBV clones were generated from serial serum samples of five chronic hepatitis B patients who received sequential NUC therapies (treated patients) and two untreated patients
Ying-Zi, Tang   +4 more
openaire   +2 more sources

Prognosis of hepatitis B‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents

Journal of Gastroenterology and Hepatology, 2012
AbstractBackground and Aim:  We investigated long‐term outcomes and prognostic factors in patients with hepatitis B virus (HBV)‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.Methods:  Between January 1999 and February 2009, a total of 240 consecutive patients who had HBV‐related cirrhosis without malignancy were ...
Chang Ha, Kim   +12 more
openaire   +2 more sources

A case of chronic hepatitis B complicated by systemic sarcoidosis that regressed following nucleos(t)ide analog therapy

Clinical Journal of Gastroenterology
Herein, we report the case of a 75-year-old woman with systemic sarcoidosis complicated by chronic hepatitis B. She presented with high fever and fatigue, with imaging studies revealing multiple tumor nodules in the liver and spleen, along with generalized lymphadenopathy, leading to her admission to our hospital for further evaluation and treatment ...
Shigeaki Semba   +9 more
openaire   +2 more sources

Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift

Hepatology International, 2019
Potent nucleos(t)ide analogs (NUC), such as entecavir and tenofovir disoproxil fumarate, are able to suppress HBV DNA to undetectable level. These agents have no direct action on cccDNA, which is a very stable template for HBV production, hence long-term or even life-long NUC therapy is required in HBeAg-negative patients to maintain HBV suppression ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy